RET and medullary thyroid gland carcinoma: Both VEGFR2 and RET protooncogenes in MTC are targeted by the superior dual inhibitor, AGN-PC-0CUK9P, and thus, AGN-PC-0CUK9P may be used for improving the therapy of MTC [30].